Knowledge Center

Kirkland’s Announces New Share Repurchase Program

On September 24, Kirkland’s, Inc. (KIRK) announced that its Board of Directors authorized a new share repurchase program. The new program allows the company to repurchase up to $10 million worth of common shares. Kirkland’s still has $2.9 million available from its previous $10 million share repurchase program.   Sonal alerted subscribers of the event […]

Read more...

Akcea and Ionis Announce Positive Phase 2 Clinical Trial Results

Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (IONS), announced positive topline clinical trial results on September 24. The Phase 2 clinical trial is studying the effect of AKCEA-APO(a)-LRx on patients with established cardiovascular disease and elevated levels of lipoprotein(a), known as Lp(a). The goal of the Phase 2 clinical study was to […]

Read more...

Progenics Pharmaceuticals Reports Top Line Phase 3 Clinical Trial Results

On September 13, Progenics Pharmaceutical, Inc. (PGNX) reported Phase 3 clinical trial results from its study of 1404, the company’s prostate specific membrane antigen (PSMA). It is a targeted small molecule SPECT/CT imaging agent designed to visualize prostate cancer. The results met one of the co-primary endpoints of identifying patients without clinically significant prostate cancer. […]

Read more...

August 2018 Scorecard

The August 2018 scorecard for the signals generated from Sonal can be downloaded here. For more information regarding how you can trade these signals, see the article The Three Moves for Event Based Trading Try Sonal 30 days for free and cancel anytime! Subscribe here and check out the Quickstart Guide

Read more...

INSYS Therapeutics Receives FDA Fast Track Designation for Epinephrine Nasal Spray

INSYS Therapeutics, Inc. (INSY) announced on August 30 that the company received a Fast Track from the FDA for the company’s epinephrine nasal spray. The spray is an investigational drug for the treatment of anaphylaxis, a life-threatening allergic reaction requiring urgent treatment. INSYS is a leader in the development, manufacture, and commercialization of pharmaceutical cannabinoids […]

Read more...

Analog Devices Share Repurchase Program Increases by $2 Billion

On August 21, Analog Devices, Inc. (ADI) announced that the company’s Board of Directors voted to reinstate their share repurchase program. The company’s existing share repurchase program started in 2004, and Analog Devices has repurchased $5.4 billion in stock since that time. This reinstatement increases the total authorization by an additional $2 billion.   At […]

Read more...

July 2018 Scorecard

The July 2018 scorecard for the signals generated from Sonal can be downloaded here. For more information regarding how you can trade these signals, see the article The Three Moves for Event Based Trading Try Sonal 30 days for free and cancel anytime! Subscribe here and check out the Quickstart Guide

Read more...

Hemisphere Media Group Announces New Share Repurchase Program

On August 16, Hemisphere Media Group, Inc. (HMTV) announced that its Board of Directors has authorized a new $25 million share repurchase program. The new share repurchase authorization is an addition to the company’s existing $25 million share repurchase program. Hemisphere Media Group is the only U.S. media company solely focusing on the U.S. Hispanic […]

Read more...

China Rapid Finance Announces Stock Repurchase Program

China Rapid Finance Limited (XRF) announced on August 15 that its Board of Directors authorized a new share repurchase program. Under the program, the company can repurchase up to $20 million of its ordinary shares in the form of American depository shares. China Rapid Finance is one of China’s largest consumer lending marketplaces.   Sonal […]

Read more...

Regeneron Pharmacueticals and Teva Pharmaceutical Report Positive Topline Phase 3 Clinical Trial Results of Fasinumab

On August 16, Regeneron Pharmaceuticals, Inc. (REGN) and Teva Pharmaceutical Industries Ltd. (TEVA) announced positive topline results from a Phase 3 clinical trial of Fasinumbab in patients with chronic pain from osteoarthritis of the knee or hip. After 16 weeks, the study met both co-primary endpoints as well as all key secondary endpoints. Patients treated […]

Read more...